Table 1.
Patient sample and demographics data.
| Patient ID | Age (years) | Sex | Ethnicity | Nasal samples | Sputum samples | Duration between samples (days) | Treatment antibiotic | Prophylaxis antibiotic | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Pre- treatment | Post-treatment | Pre-treatment | Post-treatment | |||||||
| EXB1 | 4.1 | F | Pasifika | Y | Y | Y | NC | 14 | Oral Augmentin TDS | |
| EXB2 | 7.8 | M | Pasifika | Y | NC | Y | NC | NA | IV Augmentin Q8H | |
| EXB3 | 5.5 | M | Pasifika | UN | Y | Y | UN | 14 | Oral Augmentin TDS | |
| EXB4 | 3 | M | Pasifika | Y | Y | Y | Y | 12 | Oral Augmentin TDS | |
| EXB5 | 2.6 | M | Māori | Y | Y | Y | UN | 10 | IV Augmentin Q8H | |
| EXB6 | 5.6 | F | Māori | Y | Y | Y | Y | 14 | Oral Augmentin TDS | |
| EXB7 | 11.5 | M | Māori | Y | Y | UN | Y | 17 | IV Cefuroxime Q8H | |
| EXB8 | 10.7 | M | Pasifika | UN | Y | UN | Y | 13 | Oral Amoxycillin TDS | |
| EXB9 | 5.5 | F | Māori | Y | Y | Y | Y | 10 | IV Cefuroxime Q8H | *Oral Erythromycin BD |
| EXB10 | 10.6 | M | Māori | NC | Y | UN | Y | 9 | IV Augmentin Q8H | Oral Roxithromycin OD |
| EXB11 | 12.6 | F | Pasifika | Y | Y | UN | UN | 11 | IV Augmentin Q8H | |
| EXB12 | 7.1 | F | Pasifika | Y | Y | UN | UN | 12 | IV Cefuroxime Q8H | *Oral Augmentin BD |
| EXB13 | 3 | M | Pasifika | Y | Y | Y | Y | 6 | Oral Azithromycin OD | |
| EXB14 | 4.7 | M | Pasifika | Y | NC | Y | Y | 9 | IV Augmentin Q8H | |
| EXB15 | 11.5 | M | Māori | Y | UN | UN | Y | 8 | IV Augmentin Q8H | |
| EXB16 | 6.6 | M | Pasifika | Y | Y | UN | UN | 18 | Oral Augmentin TDS | |
| EXB17 | 1.5 | M | Māori | NC | Y | Y | Y | 20 | IV Cefuroxime Q8H | |
| EXB18 | 2.3 | M | Māori | NC | NC | Y | Y | 10 | IV Augmentin Q8H | |
| EXB19 | 1.9 | F | Pasifika | Y | NC | Y | NC | NA | Oral Augmentin TDS | |
| EXB20 | 4 | M | Māori | NC | NC | Y | Y | 6 | IV Augmentin Q8H | |
| EXB21 | 2.3 | M | Pasifika | Y | Y | Y | Y | 14 | Oral Augmentin TDS | |
| EXB22 | 2.1 | F | Pasifika | Y | Y | Y | Y | 14 | Oral Augmentin TDS | |
| EXB23 | 4.8 | F | Māori | Y | Y | NC | Y | 13 | IV Augmentin Q8H | |
| EXB24 | 14 | F | Asian | Y | Y | Y | Y | 10 | IV Cefuroxime Q8H | |
| EXB25 | 3.6 | M | Pasifika | Y | Y | Y | Y | 29 | Oral Augmentin TDS | |
| EXB26 | 11.9 | M | Pasifika | NC | NC | Y | NC | NA | IV Augmentin Q8H | Oral Azithromycin OD |
| EXB27 | 13.5 | M | Pasifika | NC | NC | Y | Y | 9 | IV Augmentin Q8H | |
| EXB28 | 11.4 | M | Pasifika | NC | NC | Y | NC | NA | IV Cefuroxime Q8H | |
| EXB29 | 11 | F | Māori | Y | UN | Y | UN | 13 | IV Cefuroxime Q8H | |
| EXB30 | 15 | F | European | Y | UN | Y | Y | 14 | IV Cefuroxime Q8H | |
Key demographics of patient population. *Indicates that prophylaxis antibiotic treatment was suspended while this patient was on the exacerbation treatment. Y, Sequence data available for analysis; NC, Sample not collected; UN, Sample was collected but failed to generate usable sequence data. IV, intravenous; NA, not available.